18F-FDG PET/CT在造血干细胞移植后淋巴细胞增殖性疾病中的初步应用

doi:DOI:10.12117/jccmi.2019.12.002

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To evaluate usefulness of fluorine-18 2-fluoro-2-deoxyglucose PET and computed tomography(18F-FDG PET/CT) in post-transplant lymphoproliferative disorder(PTLD) after hematopoietic stem cell transplantation(HSCT). Methods: From January 2008 to October 2017, the records of all patients that had undergone 18F-FDG PET/CT for evaluation of PTLD after HSCT were analyzed retrospectively. A chart review of clinical information was performed, the imaging features of 18F-FDG PET/CT were reported, and its role in guiding biopsy and evaluating treatment response following therapy was assessed. Results: A total of 9 patients(7 male and 2 female; 18~35 years of age, average: 24 years) were identified. Among them, 6 cases were diagnosed as PTLD based on the pathological result, and another 3 had been treated for PTLD based on clinical findings, elevated EBV, and positive imaging findings. Nine patients had a total of 18 18F-FDG PET/CT scans prior to or following HSCT. Both lymph nodal and extranodal sites of involvement could be detected on 18F-FDG PET/CT images, which showed more lymph node lesions rather than extranodal lesions, and both types of lesions demonstrated increased 18F-FDG uptake. Five patients underwent biopsy guided by 18F-FDG PET/CT images. The biopsy results of 5 cases were positive for PTLD, including polymorphic subtype in 2 cases, polymorphic subtype with local diffuse large B cell lymphoma change in 1 case and diffuse large B-cell lymphoma in 2 cases. One patient underwent biopsy based on palpable cervical lymph nodes and the result was reactive hyperplasia of lymph nodes which was negative for PTLD. There was 1 patient with multiple involvement of the central nervous system which was diffuse large B cell lymphoma on final histology after resection. The corresponding therapeutic protocol was reviewed. Six patients underwent 18F-FDG PET/CT scans to evaluate treatment response following therapy, and all were demonstrated improvement. Conclusion: 18F-FDG PET/CT plays an important role in imaging diagnosis, guided biopsy and therapeutic evaluation of PTLD patients after hematopoietic stem cell transplantation.

Key words： Lymphoproliferative disorders Hematopoietic stem cell transplantation Fluorodeoxyglucose F18;

Received: 09 October 2019

PACS:	Ｒ457.7
	Ｒ557.4
	Ｒ817.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Xiao-chun1
	WANG Si-yun1
	WANG Shu-xia1
	DENG Ning-hong2

Cite this article:

ZHANG Xiao-chun1,WANG Si-yun1,WANG Shu-xia1, et al. Preliminary application of 18F FDG-PET/CT in post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation[J]. JOURNAL OF CHINA MEDICAL IMAGING, 2019, 30(12): 840-846.

URL:

http://www.jccmi.com.cn/EN/DOI:10.12117/jccmi.2019.12.002 OR http://www.jccmi.com.cn/EN/Y2019/V30/I12/840

[1]Bianchi E, Pascual M, Nicod M, et al. Clinical usefulness of FDG-PET/CT scan imaging in the management of post-transplant lymphoproliferative disease[J]. Transplantation, 2008, 85(5): 707-712. [2]Noraini AR, Gay E, Ferrara C, et al. PET-CT as an effective imaging modality in the staging and follow-up of post-transplant lymphoproliferative disorder following solid organ transplantation[J]. Singapore Med J, 2009, 50(12): 1189-1195. [3]Blaes AH, Morrison VA. Post-transplant lymphoproliferative disorders following solid-organ transplantation[J]. Expert Rev Hematol, 2010, 3(1): 35-44. [4]LaCasce AS. Post-transplant lymphoproliferative disorders[J]. Oncologist, 2006, 11(6): 674-680. [5]Loren AW, Porter DL, Stadtmauer EA, et al. Post-transplant lymphoproliferative disorder: a review[J]. Bone Marrow Transplant, 2003, 31(3): 145-155. [6]Tsai DE, Aqui NA, Vogl DT, et al. Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene[J]. Am J Transplant, 2005, 5(8): 2070-2073. [7]Borhani AA, Hosseinzadeh K, Almusa O, et al. Imaging of posttransplantation lymphoproliferative disorder after solid organ transplantation[J]. Radiographics, 2009, 29(4): 981-1000. [8]Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications[J]. Blood, 2011, 117(19): 5019-5032. [9]Takehana CS, Twist CJ, Mosci C, et al. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder[J]. Nucl Med Commun, 2014, 35(3): 276-281. [10]Vali R, Punnett A, Bajno L, et al. The value of 18F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis[J]. Pediatr Transplant, 2015, 19(8): 932-939. [11]Scarsbrook AF, Warakaulle DR, Dattani M, et al. Post-transplantation lymphoproliferative disorder: the spectrum of imaging appearances[J]. Clin Radiol, 2005, 60(1): 47-55. [12]Evans IV, Belle SH, Wei Y, et al. Post-transplantation growth among pediatric recipients of liver transplantation[J]. Pediatr Transplant, 2005, 9(4): 480-485. [13]Rakheja R, Makis W, Skamene S, et al. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients[J]. AJR, 2012, 198(198): 1409-1416. [14]Metser U, Lo G. FDG-PET/CT in abdominal post-transplant lymphoproliferative disease[J]. Br J Radiol, 2016, 89(1057): 20150844. [15]Rouce RH, Louis CU, Heslop HE. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant[J]. Curr Opin Hematol, 2014, 21(6): 476-481. [16]Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation[J]. Am J Transplant, 2006, 6(2): 262-274. [17]Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?[J]. Am J Surg Pathol, 2000, 24(3): 375-385. [18]Yang J, Zhuang H. The role of 18F-FDG PET/CT in the evaluation of pediatric transplant patients[J]. Hell J Nucl Med, 2015, 18(2): 136-139. [19]Everly MJ, Bloom RD, Tsai DE, et al. Posttransplant lymphoproliferative disorder[J]. Ann Pharmacother, 2007, 41(11): 1850-1858. [20]Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group[J]. J Clin Oncol, 2014, 32(27): 3048-3058. [21]Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma[J]. J Clin Oncol, 2007, 25(5): 571-578. [21]李可心，孙洪赞，郭启勇. PET与WB-DWI诊断肿瘤及炎症疾病的研究进展[J]. 中国临床医学影像杂志，2018，29（4）：291-294.